Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer — PLATON  

Prostate Cancer Metastatic Clinical Trial

Official title: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]

Status Recruiting

Clinical Trial Summary

The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to treat this disease.

Clinical Trial Description

The standard or usual treatment for this disease is systemic therapy, which includes androgen deprivation therapy (ADT) with or without chemotherapy or hormone therapy. Additionally, for some patients with specific disease features, standard treatment may also include ablative treatment (radiation or surgery) of the prostate gland if this was not completed prior to enrolling into this study.

Ablative Therapy is a procedure used to destroy cancer cells and tissue. In this study Stereotactic Body Radiation Therapy (SBRT) or surgery will be used to destroy prostate cancer metastases. It is not clear if ablative therapy (SBRT or surgery) to all sites of disease used in combination with standard systemic therapy can offer better results than standard treatment alone. ;

Related Conditions & MeSH terms

• Prostate Cancer Metastatic
• Prostatic Neoplasms

• NCT number: NCT03784755
• Study type: Interventional
• Source: Canadian Cancer Trials Group
• Contact: Wendy Parulekar
• Phone: 613-533-6430
• Email: wparulekar@ctg.queensu.ca
• Status: Recruiting
• Phase: N/A
• Start date: November 15, 2019
• Completion date: July 30, 2027